Dr Lal PathLabs shares hit a 52-week high of Rs 2,049.00, up 6%, after a 27.6% Q2 profit rise to Rs 192.2 crore and a Rs 5 interim dividend.

Dr. Lal Path Labs Ltd. told exchanges on 4 November that consolidated net profit for the July to September quarter rose 27.6% to Rs 192.2 crore, up from Rs 150.6 crore a year earlier.

Revenue from operations climbed 19.6% to Rs 873.9 crore from Rs 730.6 crore.

Operating profit, also called EBITDA, rose about 25% to Rs 280 crore from Rs 224.1 crore, and the margin widened to 32.1% from 30.7%.

In simple terms, the diagnostics chain kept more of each rupee it earned. Shareholders get a payout too.

The board approved a second interim dividend for FY27 of Rs 5 per share, which is 50% of the Rs 10 face value.

The record date, the cut-off for who qualifies, is 11 November. Payment will follow within 30 days of the declaration.

The board made two other decisions. It appointed Vasuta Agarwal as a non-executive independent director for three years from 4 November.

It also cleared an investment of up to Rs 49.5 crore, in one or more instalments, in its wholly owned Dubai arm, Dr. Lal PathLabs FZCO, so that arm can meet its business needs, including further investment in its own Ghana subsidiary, Sunshine Healthcare Limited.

Earlier this year, shareholders also received a Rs 4 dividend that went ex-dividend on 25 June and a Rs 5 interim dividend that went ex-dividend on 30 July.

Dr Lal PathLabs shares closed at Rs 2,029.40 on NSE, up by 5.39% from that previous close.

About 7.35 lakh shares, worth Rs 144.96 crore, changed hands during the day. It’s up 35.45% in 2026, and the company’s market value is Rs 34,063.24 crore.

Want to look beyond tips and market noise? Explore market sentiment, money flows and research-backed trade ideas—all in one app. Download Intraday Traders by EquityPandit and stay informed.